Clinical trial NCT00247000: A Strategy of Home Telehealth for Management of Congestive Heart Failure(STARTEL)
Official title: A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure
Keywords: Cardiovascular Diseases
Heart Disease
Heart Failure,Congestive
Health Outcomes
Disease Management
Telehomecare
Home Telehealth
Lead sponsor: Nova Scotia Health Authority
Sponsor class: OTHER
Collaborators: name: Atlantic Health Sciences Corporation
name: Heart and Stroke Foundation of Canada
name: Canada Health Infoway
name: Continuing Care Nova Scotia
name: Nova Scotia Telehealth Program
name: AstraZeneca
First posted: 2005-11-01
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: To demonstrate the safety, feasibility, quality of life, primary caregiver satisfaction, and cost effectiveness of integrated Home Telehealth care versus standard care in a heart failure clinic.

Detailed description: We plan to implement and evaluate a Home Telehealth Care Management System designed to enhance clinical care for congestive heart failure patients who have difficulty with access to care. Unique in this model is that in addition to use of protocol driven interventions (evidence based), the primary care physician is intimately involved in follwo up of patients- with consequent reduction in the fracture of care seen in with attendance in multiple specialty clinics.

In this project, we will evaluate the delivery of care to heart failure patients in Nova Scotia and New Brunswick, with our intervention and the current standard of care, which is the heart failure clinic. Home Telehealth technology will allow patients to be contacted and regularly evaluated in a comprehensive way in their own home, and without the need for a clinic visit. While the Project Team (experienced in heart failure management) will monitor all data, the Family Physician will have first hand access to and right of first treatment when alterations in therapy are needed. This process will be facilitated by the use of protocol driven medical therapy, and delegated medical functions, as well as set-piece education. We hope, with this technology and care plan, to offer the benefits of disease management to this vulnerable patient population while at the same time firmly placing the Family Physician in their central role within the health care system. This program will enable a specific assessment of all aspects of the program, including outcomes, quality of life, professional satisfaction and cost.

Eligibility criteria: Patient Population Inclusion Criteria: Patients are eligible for participating in STARTEL if they satisfy all of the following inclusion criteria.

1. Male or female subject's ≥ 18 years of age with a diagnosis of Heart Failure
2. Subject must reside in either the Province of Nova Scotia or New Brunswick
3. Subject has been hospitalized for heart failure during the past two years or has a known history of heart failure for a minimum of two years.
4. Subject must have a dedicated working telephone line in their primary place of residence.
5. Subject must have a grounded electrical power supply in their primary place of residence.
6. Primary care physician provides their agreement to participate in STARTEL

Exclusion Criteria: Patients are not eligible for participating in STARTEL if they meet any of the following exclusion criteria.

1. Inability to understand the English or French language or understand the study and provide informed consent.
2. Absence of a suitable area to conduct the home telehealth visit in the patient's place of residence.
3. Physical impairment, which would prohibit the successful completion of a home telehealth visit, including attachment of the peripheral equipment (BP cuff, ability to stand on a scale, etc).
4. In cases 1 \& 3 only: a live in caregiver whose presence may overcome these limitations may allow the patient to be included in the study, however, only the patient's next of kin or duly appointed guardian (with documentation and with patient assent) may provide informed consent to participate).
5. Subject has a planned cardiac procedure such as open-heart surgery or percutaneous coronary intervention (PCI) within the next 6 months.
6. Subject has had cardiac surgery, percutaneous coronary intervention or a diagnosis of acute myocardial infarction within 1 month before randomization).
7. Condition where existing routine follow up occurs more than once weekly (i.e. hemodialysis, cancer treatment including: chemotherapy/radiation treatment). .
8. Patient is institutionalized (includes chronic care facility)

Primary outcomes:
measure: A composite of total all-cause hospitalizations and total mortality at one year.
timeFrame: 1 year
Secondary outcomes:
measure: Heart failure morbidity and mortality
timeFrame: 1 year
measure: Cardiovascular hospitalization
timeFrame: 1 year
measure: Total number days in hospital
timeFrame: 1 year
measure: Total outpatient physician visits
timeFrame: 1 year
measure: Number of non-scheduled health visits outside the home
timeFrame: 1 year
measure: Total inpatient and outpatient health care costs
timeFrame: 1 year
measure: Kansas City Cardiomyopathy Quality of Life Score
timeFrame: 1 year
measure: Total medication related costs
timeFrame: 1 year
measure: Medication adherence(by prescription filling data)
timeFrame: 1 year
measure: Patient satisfaction as measured on Likert scale(1-10)
timeFrame: 1 year
measure: Primary care physician satisfaction (Likert scale)
timeFrame: 1 year
Other outcomes:
Locations:
city: Saint John
country: Canada
facility: New Brunswick Heart Centre, Atlantic Health Sciences Corporation
state: New Brunswick
Study officials:
affiliation: Capital District Health Authority, QEII Health Sciences Centre
name: Jonathan G Howlett, M.D.,FRCPC
role: PRINCIPAL_INVESTIGATOR
References: